Clinical trials: Primary Angle Closure Glaucoma
Glaucoma
Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?
The investigators hypothesize that intracameral Triesence during glaucoma surgery will provide lower intraocular pressure through better control of ocular inflammation, thus leading to a more successful filtering procedure.
- Trial name
- NCT00853905
- Testing
- Triesence, balanced salt solution BSS
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Wills Eye
Primary Angle-Closure Glaucoma, Primary Angle Closure Without Glaucoma Damage
Phacoemulsification Versus Phacoemulsification With Micro-bypass Stent
Assessing the safety and efficacy of a micro-bypass stent in combination with cataract surgery in subjects with primary angle closure.
- Trial name
- NCT03647033
- Testing
- iStent implantation
- Where
- Singapore
- Volunteers
- 32 people
- Sponsor
- Khoo Teck Puat Hospital
Angle-closure Glaucoma
Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma…
- Trial name
- NCT00762645
- Testing
- Travoprost 0.004% (Travatan), Pilocarpine 1%
- Volunteers
- 30 people
- Sponsor
- Alcon Research
Intraocular Pressure
Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily.
- Trial name
- NCT00758342
- Testing
- Travoprost 0.004% + Brinzolamide 1.0%, Travoprost 0.004% + Tears Natural
- Volunteers
- 37 people
- Sponsor
- Alcon Research
Glaucoma, Angle-Closure
Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with Angle Closure Glaucoma.
- Trial name
- NCT03362931
- Testing
- XEN45
- Where
- 16 sites in Australia, Canada and 4 more
- Volunteers
- 65 people
- Sponsor
- Allergan